Marathon Asset Management Amends Term Loan Facility with Theratechnologies
Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, entered into a first amendment to its credit agreement dated July 20, 2022 with certain funds and accounts for which Marathon Asset Management acts as investment manager.
March 1, 2023
Marathon Asset Management | Paul Lévesque | Theratechnologies
Ian Koplin